NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

Is BioMarin a Bargain After 21% Drop and Regulatory News in 2025?

Wondering if BioMarin Pharmaceutical is a hidden gem or an opportunity that's passed you by? Let's dig into what we can actually learn from the data, especially if you're curious about whether it looks undervalued right now. The stock has seen some notable downside lately, dropping 5.2% over the last month and 21.0% year-to-date. This could signal changing risk perceptions or even a potential bargain. Market sentiment recently cooled after regulatory developments in the rare disease space...
NasdaqGM:AXSM
NasdaqGM:AXSMPharmaceuticals

Axsome Therapeutics (AXSM): Exploring Valuation as Shares Climb 54% Year-to-Date

Axsome Therapeutics (AXSM) shares have delivered a steady run lately, climbing 12% over the past month and up more than 50% this year. Investors are considering how current momentum relates to company performance and future prospects. See our latest analysis for Axsome Therapeutics. Momentum has clearly been building for Axsome Therapeutics, with the share price up over 54% year-to-date and the 1-year total shareholder return exceeding 51%. This sustained outperformance suggests growing...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

AeroVironment (AVAV): Assessing Valuation After Strategic Move to Standardize AV_Halo Command With OpenJAUS Collaboration

AeroVironment (AVAV) just announced a new collaboration with OpenJAUS to integrate the JAUS standard into its AV_Halo Command platform. This move provides streamlined and unified control to uncrewed systems across manufacturers, making it easier for defense operators to manage complex platforms. See our latest analysis for AeroVironment. After integrating the JAUS standard with AV_Halo Command, AeroVironment continues to build momentum, fresh off a $95.9 million Army contract for its LRKI...
NYSE:OGS
NYSE:OGSGas Utilities

ONE Gas (OGS) Margin Growth Reinforces Defensive Narrative Despite Cautious Valuation Signals

ONE Gas (OGS) reported net profit margins of 10.8%, slightly ahead of last year’s 10.5%, as annual earnings growth reached 17.7%, substantially outpacing the company’s five-year average of 4.5%. Earnings are forecast to grow at 8.94% per year, but both profit and revenue trends remain below broader US market averages. Investors will note that despite stronger bottom-line results, valuation appears mixed given that the stock’s Price-to-Earnings ratio sits between its US and global gas utility...
NYSE:OKE
NYSE:OKEOil and Gas

Does ONEOK’s 36.8% Drop Signal a Missed Opportunity in 2025?

Wondering if ONEOK might be a hidden value in the energy sector? Let’s dig into whether the numbers back up that gut feeling, especially if you are looking for opportunities others might have missed. The stock has had a rough patch recently, sliding 6.9% over the past week and 11.8% over the last month, with a year-to-date drop of 36.8% and a one-year loss of 31.4%. Looking at a longer timeline, over five years shares are still up an impressive 164.5%. Some of the recent price movement...
NYSE:MRK
NYSE:MRKPharmaceuticals

Blackstone Funding Deal Might Change the Case For Investing In Merck (MRK)

Merck recently announced an agreement to receive US$700 million in funding from Blackstone Life Sciences to advance the development of sacituzumab tirumotecan, an investigational cancer therapy, in exchange for future royalties contingent on regulatory approval and successful clinical trial outcomes. This partnership allows Merck to accelerate innovation while retaining full control over development and commercialization of the candidate. The collaboration with Blackstone underscores...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

A Look at SEI Investments’s (SEIC) Valuation Following Q3 Growth and New Platform Adoption

SEI Investments (SEIC) just reported higher revenue and net income for the third quarter, highlighting ongoing business momentum. At the same time, Clermont Trust USA became the latest client to adopt the SEI Wealth Platform. See our latest analysis for SEI Investments. Momentum seems to be building for SEI Investments, with the recent Clermont Trust USA win and ongoing buybacks bringing attention to its steady business expansion. The stock’s latest share price is $81.64, and while...
NasdaqGS:WDC
NasdaqGS:WDCTech

Is It Too Late to Consider Western Digital After 200% Share Price Surge?

Wondering if Western Digital’s rapid rise means it’s still a bargain, or if you’ve already missed the boat? Let’s break down what’s really driving interest in this tech stock right now. Western Digital’s share price has soared, up 21.8% over the last week, another 15.9% in the past month, and an incredible 202.3% in the past year. This hints at both strong momentum and possibly shifting risk perceptions among investors. Recent headlines about Western Digital’s strategic positioning in AI...
NYSE:ACHR
NYSE:ACHRAerospace & Defense

Is Archer Aviation's (ACHR) Asset-Light Strategy the Key to Unlocking Sustainable Profitability?

Recent analysis has highlighted Archer Aviation's asset-light manufacturing strategy and its focus on both commercial air taxi and defense markets. This approach, combined with a substantial cash position and an identified route towards profitability, is increasing Archer's distinction among its sector peers. Let's look at how the company's focus on upside potential and a clear path to profitability shapes Archer's investment narrative. We've found 20 US stocks that are forecast to pay a...
NasdaqGM:HRMY
NasdaqGM:HRMYPharmaceuticals

Harmony Biosciences (HRMY) Profit Margin Surpasses Expectations, Reinforcing Growth-Focused Investor Narrative

Harmony Biosciences Holdings (HRMY) delivered a net profit margin of 22.5% this period, well above last year's 18%. Earnings grew by 51.4% over the past year, outpacing both its own five-year average growth rate of 40.8% and broader US market expectations. Looking ahead, analysts forecast earnings to grow 20.5% per year, surpassing the US market's 16%, while revenue is expected to rise at 12.7% annually compared to the market's 10.5% pace. This combination of sustained profitability and...
NYSE:CHWY
NYSE:CHWYSpecialty Retail

Should Chewy's (CHWY) Chewy+ Price Hike Shift Investor Views on Its Recurring Revenue Strategy?

Chewy has raised its Chewy+ membership fee from US$49 to US$79, reflecting management’s confidence in the premium program’s value proposition and positioning for increased revenue potential. This move, paired with sustained positive analyst sentiment, highlights the company’s emphasis on recurring revenue streams and its continued momentum with both investors and customers. We'll examine how Chewy's increase in Chewy+ membership fee could influence the company’s growth outlook and investment...
NasdaqGS:PRLD
NasdaqGS:PRLDBiotechs

Why Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Backs $25M Private Placement - And What's Next

On November 3, 2025, Prelude Therapeutics announced a private placement, raising US$25,000,000 by issuing 6,250,000 shares at US$4 each, with participation from Incyte Corporation. Institutional interest from a company like Incyte can be viewed as an endorsement of Prelude’s research direction and funding outlook. We’ll explore how Incyte’s involvement in the private placement shapes Prelude’s investment narrative and financial flexibility. The best AI stocks today may lie beyond giants like...
NYSE:HL
NYSE:HLMetals and Mining

Hecla Mining (HL): Evaluating Valuation After a Strong Multi-Month Rally

Hecla Mining (HL) shares have seen a modest bump this month, with the stock up just under 1%. Investors are keeping a close eye on how its performance lines up with broader trends in the metals sector. See our latest analysis for Hecla Mining. Hecla Mining’s share price may have treaded water over the past month, but the real story is its eye-catching 96% gain over the last three months and a year-to-date share price return of 128%. With metals prices in focus and sector momentum building,...
NYSE:EXPD
NYSE:EXPDLogistics

Expeditors (EXPD) Profit Margin Improvement Challenges Sector Concerns on Earnings Sustainability

Expeditors International of Washington (EXPD) reported a net profit margin of 7.6%, up from 7.4% a year ago, signaling a modest expansion in profitability. Earnings grew 15.4% over the past year. However, the longer-term five-year trend shows a decline of 6% per year. Looking ahead, analysts expect earnings to decline by 1.1% annually over the next three years, along with minimal revenue growth of 0.2% per year. This trails well behind the broader US market's projected 10.5% annual rate. The...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Collegium Pharmaceutical (COLL): Examining the Stock’s Valuation After Recent Gains

Collegium Pharmaceutical (COLL) has shown steady gains over the past month, with the stock advancing 3% and building on its momentum from the past 3 months, where returns top 20%. This trend has caught the attention of many investors. See our latest analysis for Collegium Pharmaceutical. After a sustained climb over the past quarter, Collegium Pharmaceutical’s 20.2% 3-month share price return has helped drive a more robust year-to-date move. However, the 1-year total shareholder return is a...
NYSE:GBCI
NYSE:GBCIBanks

Did Glacier Bancorp's (GBCI) New Shelf Registration Just Shift Its Investment Narrative?

Glacier Bancorp, Inc. recently filed a shelf registration, allowing it to issue various securities such as common and preferred stock, depositary shares, debt securities, warrants, rights, and units in the future. This new shelf registration offers the company increased flexibility to strengthen its capital base as it pursues further growth and manages industry uncertainties. We’ll examine how this expanded funding capability could influence Glacier Bancorp’s investment narrative and future...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

Why TransMedics Group (TMDX) Is Up After Raising 2025 Revenue Outlook and Posting Strong Q3 Results

TransMedics Group reported strong third quarter financial results, with revenue for the period ending September 30, 2025 reaching US$143.82 million and net income of US$24.32 million. The company also raised its full-year 2025 revenue guidance mid-point, reflecting management's confidence in ongoing adoption of its transplant technology across key markets. We’ll explore how TransMedics’ upgraded revenue outlook may influence analyst expectations for the company’s longer-term earnings...
NasdaqGS:CSGS
NasdaqGS:CSGSProfessional Services

A Look at CSG Systems International’s (CSGS) Valuation Following Its 2024 Share Price Rally

CSG Systems International (CSGS) has seen its stock climb more than 20% in the past month and almost 55% since the start of the year. This steady momentum has sparked fresh discussion about its current valuation. See our latest analysis for CSG Systems International. After a breakout stretch, CSG Systems International’s short-term momentum has accelerated, with a 1-month share price return of over 20%. This builds on a substantial year-to-date share price gain of nearly 55%, and the company’s...
NasdaqGS:PEBO
NasdaqGS:PEBOBanks

Is Peoples Bancorp a Bargain After 4% Weekly Decline?

Ever wondered if Peoples Bancorp is trading at a bargain or a premium? You are not alone, especially with all the chatter about value in today’s markets. After a steady run in recent years, the stock has faced some turbulence, sliding by 4.0% over the past week and down 9.0% year-to-date. However, it still boasts a 41.3% gain over five years. Recent headlines have put the spotlight on regional banks as market sentiment shifts around interest rate expectations and broader financial sector...
NasdaqGS:STEP
NasdaqGS:STEPCapital Markets

Assessing StepStone Group After Fund Launches and a 5.9% Yearly Share Price Gain

Wondering if StepStone Group is a hidden gem or getting pricey? You are not alone, and we're here to break down the numbers in plain English. The stock has seen returns of 5.4% year-to-date and 5.9% over the last year, despite minor pullbacks in the last week and month. StepStone's share price has been influenced by recent headlines detailing its continued expansion in private markets and new fund launches, which have caught the eye of both industry watchers and investors. This activity has...
NasdaqGS:NSIT
NasdaqGS:NSITElectronic

A Deep Dive Into Insight Enterprises (NSIT) Valuation After Recent Share Price Weakness

Insight Enterprises (NSIT) has seen its stock decline about 18% over the past 3 months, with shares currently trading around $95. The company’s returns have trended downward this year. This trend has prompted investors to revisit its recent results and business outlook. See our latest analysis for Insight Enterprises. After a sharp pullback this month, Insight Enterprises is now sitting at a multi-year low. This reflects fading momentum and a sizable shift in sentiment. The stock’s 1-year...
NYSE:MSI
NYSE:MSICommunications

Can Motorola Solutions' (MSI) Steady Earnings and Buybacks Sustain Its Long-Term Growth Ambitions?

On October 30, 2025, Motorola Solutions reported third-quarter revenue of US$3.01 billion, up from US$2.79 billion a year prior, with net income unchanged at US$562 million, and provided fourth-quarter 2025 earnings guidance expecting approximately 11% revenue growth year-over-year, while maintaining its full-year 2025 revenue outlook of about US$11.65 billion. The company also completed repurchases of 258,843 shares between June and September 2025 for US$120.91 million, reflecting ongoing...
NasdaqGM:BETR
NasdaqGM:BETRDiversified Financial

Assessing Better Home & Finance (BETR) Valuation Following Activist Investor Eric Jackson’s AI-Driven Endorsement

Better Home & Finance (BETR) is in the spotlight after activist investor Eric Jackson endorsed the company for its ability to transform the mortgage sector using AI and digital technologies. Jackson drew comparisons to top e-commerce innovators. See our latest analysis for Better Home & Finance Holding. Shares of Better Home & Finance have been on a tear, climbing a remarkable 609.96% year-to-date in terms of share price return, with explosive momentum particularly in the last quarter. While...
NYSE:ELV
NYSE:ELVHealthcare

A Fresh Look at Elevance Health (ELV) Valuation Following Coverage Expansion and Analyst Upgrades

Elevance Health (ELV) recently updated its medical policy to include coverage for histotripsy, a noninvasive therapy for liver tumors. At the same time, multiple analysts have revisited their outlooks for the company, reflecting evolving investor sentiment. See our latest analysis for Elevance Health. Elevance Health’s broadened coverage for histotripsy arrives alongside notable market volatility. After a dip of nearly 10% in the last month and a strong 14.6% rebound over the previous 90...